Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients

被引:0
|
作者
Zhang, Xiaomin [1 ]
Yang, Jieli [1 ]
Chen, Sai [1 ]
Liu, Chang [1 ]
Wang, Zhenhua [1 ]
Ren, Hefei [1 ]
Zhou, Lin [1 ]
机构
[1] Naval Med Univ, Shanghai Changzheng Hosp, Dept Lab Med, 415 Fengyang Rd, Shanghai 200003, Peoples R China
基金
中国国家自然科学基金; 芬兰科学院;
关键词
Hypertension; Multiple myeloma; Progression-free survival; Risk stratification; BLOOD-PRESSURE; PARATHYROID-HORMONE; CANCER; RISK; CELLS; INTERLEUKIN-6; INFLAMMATION; MEDICATIONS; CALCIUM;
D O I
10.1007/s11239-022-02653-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately 31% of patients diagnosed with multiple myeloma (MM) have pre-existing hypertension, but its effects on patient survival have not been investigated. We collected data from 228 newly diagnosed patients with MM and found that 71 (31.1%) had pre-existing hypertension. The impact of pre-existing hypertension on MM patients was determined by evaluating progression-free survival (PFS). Kaplan-Meier analyses revealed a significantly lower PFS in the pre-existing hypertension group than their non-hypertensive counterparts (median 22.6 vs 34.8 months, respectively). The multivariable Cox proportional hazards model showed that pre-existing hypertension was an independent risk factor for PFS reduction in MM patients. Moreover, the risk of disease progression in MM patients with pre-existing hypertension was higher than in non-hypertension comparator patients (hazard ratio 1.735, 95% confidence interval 1.261-2.387). In MM patients with pre-existing hypertension, Kaplan-Meier analyses found that those with a higher risk of hypertension had a significantly shorter PFS than those with lower risk (median 19.3 vs 25.4 months, respectively). However, multivariate Cox regression analysis showed that the risk stratification of hypertension was not an independent risk factor for poor PFS in MM patients with pre-existing hypertension. Our study demonstrates that pre-existing hypertension was significantly associated with a lower PFS in newly diagnosed MM patients.
引用
收藏
页码:542 / 549
页数:8
相关论文
共 50 条
  • [1] Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients
    Xiaomin Zhang
    Jieli Yang
    Sai Chen
    Chang Liu
    Zhenhua Wang
    Hefei Ren
    Lin Zhou
    Journal of Thrombosis and Thrombolysis, 2022, 54 : 542 - 549
  • [2] Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma
    Caro, Jessica
    Cairns, David
    Menzies, Tom
    Pawlyn, Charlotte
    Boyle, Eileen M.
    Morgan, Gareth
    Cook, Gordon
    Kaiser, Martin F.
    Owen, Roger G.
    Gregory, Walter M.
    Jackson, Graham H.
    Walker, Brian
    Heaney, Jennifer Lj
    Drayson, Mark T.
    Davies, Faith E.
    BLOOD, 2020, 136
  • [3] Lower Plasma Mir-92a Levels Predict Shorter Progression-Free Survival In Newly Diagnosed Symptomatic Multiple Myeloma Patients
    Yoshizawa, Seiichiro
    Umezu, Tomohiro
    Ohyashiki, Junko H.
    Iida, Shinsuke
    Ohyashiki, Kazuma
    BLOOD, 2013, 122 (21)
  • [4] Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma
    Wani, Kashmira
    Gutta, Radhika
    Mittal, Aayush
    Jamil, Maria
    Springer, Kylie
    Kuriakose, Philip
    BLOOD, 2023, 142
  • [5] Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma
    H Einsele
    S Knop
    M Vogel
    J Müller
    M Kropff
    B Metzner
    C Langer
    H Sayer
    W Jung
    H A Dürk
    H Salwender
    H Wandt
    F Bassermann
    M Gramatzki
    W Rösler
    H-H Wolf
    W Brugger
    M Engelhardt
    T Fischer
    P Liebisch
    C Straka
    Leukemia, 2017, 31 : 1463 - 1466
  • [6] Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma
    Einsele, H.
    Knop, S.
    Vogel, M.
    Mueller, J.
    Kropff, M.
    Metzner, B.
    Langer, C.
    Sayer, H.
    Jung, W.
    Duerk, H. A.
    Salwender, H.
    Wandt, H.
    Bassermann, F.
    Gramatzki, M.
    Roesler, W.
    Wolf, H-H
    Brugger, W.
    Engelhardt, M.
    Fischer, T.
    Liebisch, P.
    Straka, C.
    LEUKEMIA, 2017, 31 (06) : 1463 - 1466
  • [7] Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma
    Daniele, Patrick
    Mamolo, Carla
    Cappelleri, Joseph C.
    Bell, Timothy
    Neuhof, Alexander
    Tremblay, Gabriel
    Musat, Mihaela
    Forsythe, Anna
    PLOS ONE, 2022, 17 (05):
  • [8] Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
    Sorrig, Rasmus
    Klausen, Tobias W.
    Salomo, Morten
    Vangsted, Annette J.
    Frolund, Ulf Christian
    Andersen, Kristian T.
    Klostergaard, Anja
    Helleberg, Carsten
    Pedersen, Robert S.
    Pedersen, Per T.
    Helm-Petersen, Sissel
    Teodorescu, Elena Manuela
    Preiss, Birgitte
    Abildgaard, Niels
    Gimsing, Peter
    PLOS ONE, 2017, 12 (12):
  • [9] MPT improves progression-free survival in elderly patients with multiple myeloma
    不详
    Nature Clinical Practice Oncology, 2009, 6 (1): : 4 - 4
  • [10] STAT3 EXPRESSION IS ASSOCIATED WITH POOR SURVIVAL IN YOUNG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Jung, S. -H.
    Choi, H. -W.
    Shin, M. -G.
    Yang, D. -H.
    Ahn, J. -S.
    Kim, Y. -K.
    Kim, H. -J.
    Lee, J. -J.
    HAEMATOLOGICA, 2015, 100 : 509 - 509